These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22231867)

  • 1. Does fingolimod in multiple sclerosis patients cause macular edema?
    Turaka K; Bryan JS
    J Neurol; 2012 Feb; 259(2):386-8. PubMed ID: 22231867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.
    Minuk A; Belliveau MJ; Almeida DR; Dorrepaal SJ; Gale JS
    JAMA Ophthalmol; 2013 Jun; 131(6):802-4. PubMed ID: 23599188
    [No Abstract]   [Full Text] [Related]  

  • 3. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
    Zarbin MA; Jampol LM; Jager RD; Reder AT; Francis G; Collins W; Tang D; Zhang X
    Ophthalmology; 2013 Jul; 120(7):1432-9. PubMed ID: 23531349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of fingolimod-associated macular edema.
    Chui J; Herkes GK; Chang A
    JAMA Ophthalmol; 2013 May; 131(5):694-6. PubMed ID: 23538612
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient.
    Saab G; Almony A; Blinder KJ; Schuessler R; Brennan DC
    Arch Ophthalmol; 2008 Jan; 126(1):140-1. PubMed ID: 18195237
    [No Abstract]   [Full Text] [Related]  

  • 6. Cystoid macular edema associated with fingolimod use for multiple sclerosis.
    Afshar AR; Fernandes JK; Patel RD; Ksiazek SM; Sheth VS; Reder AT; Hariprasad SM
    JAMA Ophthalmol; 2013 Jan; 131(1):103-7. PubMed ID: 23307220
    [No Abstract]   [Full Text] [Related]  

  • 7. Fingolimod-associated macular edema: incidence, detection, and management.
    Jain N; Bhatti MT
    Neurology; 2012 Feb; 78(9):672-80. PubMed ID: 22371414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cystoid macular oedema after fingolimod treatment in multiple sclerosis].
    Asensio-Sánchez VM; Trujillo-Guzmán L; Ramoa-Osorio R
    Arch Soc Esp Oftalmol; 2014 Mar; 89(3):104-6. PubMed ID: 24269406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.
    Fruschelli M; Capozzoli M; Gelmi MC; Masi G; Annunziata P
    Int Ophthalmol; 2019 Apr; 39(4):777-781. PubMed ID: 29500696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.
    La Mantia L; Prone V; Marazzi MR; Erminio C; Protti A
    Neurol Sci; 2014 Sep; 35(9):1485-6. PubMed ID: 24756193
    [No Abstract]   [Full Text] [Related]  

  • 11. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.
    Winges KM; Werner JS; Harvey DJ; Cello KE; Durbin MK; Balcer LJ; Calabresi PA; Keltner JL
    J Neuroophthalmol; 2013 Dec; 33(4):322-9. PubMed ID: 24051419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.
    Akiyama H; Suzuki Y; Hara D; Shinohara K; Ogura H; Akamatsu M; Hasegawa Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4180. PubMed ID: 27442641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early tolerability and safety of fingolimod in clinical practice.
    Ontaneda D; Hara-Cleaver C; Rudick RA; Cohen JA; Bermel RA
    J Neurol Sci; 2012 Dec; 323(1-2):167-72. PubMed ID: 23040960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
    Piscolla E; Hakiki B; Pastò L; Razzolini L; Portaccio E; Amato MP
    J Neurol; 2013 Jun; 260(6):1675-7. PubMed ID: 23645219
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
    Voon V; Saiva L; O'Kelly S; Keane D
    Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
    [No Abstract]   [Full Text] [Related]  

  • 18. Famous.
    Kim MJ; Bhatti MT; Costello F
    Surv Ophthalmol; 2016; 61(4):512-9. PubMed ID: 26742785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
    Pfender N; Jelcic I; Linnebank M; Schwarz U; Martin R
    Neurology; 2015 Jun; 84(23):2377-8. PubMed ID: 25957334
    [No Abstract]   [Full Text] [Related]  

  • 20. Early and recurrent macular oedema in a patient treated with fingolimod.
    Cifuentes-Canorea P; Nieves-Moreno M; Sáenz-Francés F; Santos-Bueso E
    Neurologia (Engl Ed); 2019 Apr; 34(3):206-207. PubMed ID: 27776961
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.